Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: Altargo®

ATC code: D06AX13

Substances: retapamulin


The efficacy of retapamulin in treatment of skin infections is similar in men and women. However, studies of dosing and adverse events with a relevant gender analysis are scarce.

Additional information

Pharmacokinetics an dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of retapamulin have been found.


The efficacy of topical retapamulin in patients with secondarily infected traumatic lesions was evaluated in a randomized, double-blind, placebo-controlled study (219 men, 140 women; all ages >2 months). Men/boys and women/girls receiving retapamulin had similar success rates, measured as clinical improvement [1]. Also, the original manufacturer report similar responses to retapamulin in treatment of impetigo in both sexes in clinical studies [2, 3].

Adverse events

Clinical trials of retapamulin safety have not reported sex-stratified results [1, 4].

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2016-03-29


  1. Tomayko JF, Li G, Breton JJ, Scangarella-Oman N, Dalessandro M, Martin M. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. Adv Skin Wound Care. 2013;26:113-21. PubMed
  2. ALTABAX ( retapamulin). DailyMed [www]. US National Library of Medicine. [updated 2015-04-20, cited 2016-03-29]. länk
  3. ALTABAX ( retapamulin). Labeling. U.S. Food and Drug Administration (FDA); 2012.
  4. Koning S, van der Wouden JC, Chosidow O, Twynholm M, Singh KP, Scangarella N et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-82. PubMed
  5. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-05-30.] Socialstyrelsens statistikdatabas

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson